Restless Legs Syndrome Market Trends, Size, Development, Growth and Forecast to 2020

Restless legs syndrome or RLS is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.

Restless legs syndrome increases at night when the patient is at rest. RLS are common in both, male and female; however the disease has its highest impact on woman who are elderly or in some cases woman with the age 35 to 50 years. Some of the most common symptoms of the restless legs syndrome are continue itching and pain in the legs, and unusual sleep pattern. The restless legs syndrome affects the quality of life of the person suffering from the disease.

To know more about “Restless Legs Syndrome Market” visit: www.psmarketresearch.com/market-analysis/restless-legs-syndrome-market

The exact reason behind the restless legs syndrome is not known precisely, however, it is believed the disease is caused due to genetic factors or due to iron deficiency in the brain or due to the disorders in dopaminergic balance.
The exact treatment of this disease is not present till now. However the available drug in the market helps in the indicative treatment of the disease.
Some of the drug in the restless legs syndrome market such as sulfonamide by safinamide by Newron Pharmaceuticals reduces the symptoms by novel action such as potent, reversible and selective inhibition of MAO-B, without disturbing the MAO-A and dopamine uptake. This enhances the glutamate release and dopaminergic function of the patients; it also reduces the dopamine degradation. One other drug: SER-214 manufacture by Serina is used widely in the restless legs syndrome treatment; it uses a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology this drug can be combined with the polymer and transported to the patients.

Request for TOC of “Restless Legs Syndrome Market” at: www.psmarketresearch.com/market-analysis/Restless-Legs-Syndrome-Market/toc-sample

Based on the different product type the global restless legs syndrome market can be broadly classified as Mirapex/Sifrol/Mirapexin, Neupro/Leganto, Requip, and HORIZANT/Regnite. On the basis various disease type the global restless legs syndrome market can be broadly bifurcated as etiology and pathogenesis, iron deficiency, genetic factors, neurological disturbances and others. Based on the mode of the therapy the global restless legs syndrome market can be broadly segmented into two broad categories: pharmacological therapy and non-pharmacological therapy.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/healthcare

Some of the major players operating in the global restless legs syndrome market include, GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation, Manhattan Pharmaceuticals, Boehringer Ingelheim GmbH, UCB SA.

About P&S Market Research

P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.

With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
US/ Canada Toll-Free: 1-888-778-7886
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com

347, 5th Ave. #1402
New York City, NY – 10016
US/ Canada Toll-Free: 1-888-778-7886

This release was published on openPR.